Accepted
at 11:13 p.m. Dec, 05, 2023
by
Joe
Author:
NiceJewishBoy
Co-authors:
Joe
Type of change:
Other
Rationale for change
there's a lot to remember here
Before
After
Text
Text
Text
Text
Extra
50-1000 = give more
| Pregnancy | Viral load (copies/mL) | Route of delivery | Antiretroviral therapy (ART) |
|---|---|---|---|
| ≤ 50 | Vaginal delivery | IV zidovudine not recommended | |
| > 50 - ≤ 1000 | |||
| > 1000 OR unknown viral load OR poor adherence to ARV treatment | C-section at 38 weeks | IV zidovudine 3 hours prior to delivery | |
| Newborn | Viral load (copies/mL) | Antiretroviral therapy (ART) | |
| ≤ 50 | Zidovudine within 12 hours after birth for 4 weeks | ||
| > 50 | Combo ART therapy: 3-drug combo regimen for 6 weeks | ||
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Empty field
Sketchy
Empty field
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
Empty field
OME
Additional Resources
The most important intervention for preventing the spread of HIV from mother to child is administration of combination antiretroviral therapy to the mother throughout pregnancy. Antiviral therapy should be initiated as soon as possible during pregnancy (even during the first trimester), regardless of maternal CD4 count or viral load. Antenatal combination therapy is the best way to suppress maternal HIV and prevent transplacental or perinatal acquisition by the infant. Mothers with undetectable viral loads at delivery have <1% risk of transmitting the infection to their infants. The 3-drug regimen should consist of 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor. An NRTI with good placental transfer (e.g. zidovudine, tenofovir) should be administered. Zidovudine should be administered to the neonate for >6 weeks.
One by one
Empty field